[1]Cohen S.Origins of growth factor.NGF and EGF[J].Ann NY AcadSci, 2004, 1038 (1) ∶98-102.
|
[2]Okada Y, Eibl G, Guhao S, et al.Nerve growth factor stimulatesMMP-I expression and activity and increases in vasion by humanpancreatic cancer cells[J].Clin Exp Metastasis, 2004, 21 (4) ∶285-292.
|
[3]Tokusashi Y, Asai K, Taruakawa S, et al.Expression of NGF inhepatocellular carcinoma cells with its receptors in non-tumor cellcomponents[J].Int J Cancer, 2005, 114 (1) ∶39-45.
|
[4]Dolle L, Adriaenssenes E, EI Yazidi-Belkowra I, et al.Nervegrowth factor receptors and signaling in breast cancer[J].Curr Canc-er Drug Targets, 2004, (4) ∶463-470.
|
[5]Chiaretti A, Aloe L, Antonelli A, et al.Neurotrophic factor expres-sion in childhood low-grade astrocytomas and ependymomas[J].Chids Nerv Syst, 2004, 20 (6) ∶412-419.
|
[6]Zhu ZW, Friess H, Wang L, et al.Down-regulation of Nervegrowth factor in poorly differentiated and advanced human esophagealcancer[J].Anticancer Res, 2000, 1A∶125-132.
|
[7]孙洙逸, 王磊, 杨连甲, 等.NGF在涎腺腺样囊性腺癌中的表达与嗜神经侵袭和疼痛的关系[J].第四军大学学报, 2004, 25 (11) ∶1012-1014.
|
[8]Zhu ZW, Friess H, diMola FF, et al.Nerve growth factor expressioncorrelates with perineural invasion and pair in human pancreaticcancer[J].J Clin Oncol, 1999, 17 (8) ∶2419-2428.
|
[9]Papatsoris AG, Liolitsa D, Deliveliotis C.Manipulation of the nervegrowth factor network in prostate cancer[J].Expert Opin InvestigDrugs, 2007, 16 (3) ∶303-309.
|
[10]Kruttgen A, Schneider I, Weis J.The dark side of the NGF family:neurotrophins in neoplasias[J].Brain Pathol, 2006, 16 (4) ∶304-310.
|
[11]Odegaard E, Staff AC, Abeler VM, et al.The activeated nervegrowth factor receptor p-TrKAis selectively expressed in advance-stage ovarium carcinoma[J].Hum Pathol, 2007, 38 (1) ∶140-146.
|
[12]Campos X.Munoz Y, Selman A, et al.Nerve growth factor and itshigh-affinity receptor trKA participate in the control of vascular en-dothelial growth facfor expression in epithelial ovarian cancer[J].Gy-necol Oncol, 2007, 104 (1) ∶168-175.
|
[13]Tsunoda S, Okumura T, Ito T, et al.Significance of nerve growthfactor overexpression and its autocrine loop in oesophageal squamouscell carcinoma[J].Br J Cancer, 2006, 95 (3) ∶322-330.
|
[1] | Lingling ZHU, Yani ZHANG, Tingting SHI, Yang WU, Chun GAO, Xiaohui YU, Yujing HE, Jiucong ZHANG. The role of tumor necrosis factor-α in the development and progression of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2024, 40(11): 2320-2325. doi: 10.12449/JCH241129 |
[2] | Wen QIN, Jianyu YANG, Taiwen CHEN, Haiping ZHENG, Xiaodong ZHU. Expression and significance of L1 cell adhesion molecule and transforming growth factor-β1 in pancreatic cancer tissue[J]. Journal of Clinical Hepatology, 2021, 37(6): 1404-1408. doi: 10.3969/j.issn.1001-5256.2021.06.035 |
[3] | YUSUFUKADIER·Maimaitinijiati, AIMAITI·Yasen, Li WenDing, Ran Bo, TUERGANAILI.aji, Shao YingMei, Wen Hao. Effect of the transforming growth factor-β1 signaling pathway in inducing the differentiation of hepatic progenitor cells[J]. Journal of Clinical Hepatology, 2020, 36(3): 620-623. doi: 10.3969/j.issn.1001-5256.2020.03.030 |
[4] | Mo XiaoLi, Liu Jie, Zhu JiaYu, Chen Chuang, Ou Jie, Mao SuFei. Value of transforming growth factor-β1 in diagnosis of primary liver cancer:a meta-analysis[J]. Journal of Clinical Hepatology, 2017, 33(5): 864-868. doi: 10.3969/j.issn.1001-5256.2017.05.014 |
[5] | An BaiQuan, Xin YongNing, Lu LinLin, Xuan ShiYing. Effect of PNPLA3 I148M mutation on expression of TGF- β1 in rat hepatic stellate cells[J]. Journal of Clinical Hepatology, 2016, 32(4): 769-771. doi: 10.3969/j.issn.1001-5256.2016.04.035 |
[6] | Chi ZhaoChun, Geng ZhangXin. Application of tumor necrosis factor antagonists in hepatic disease treatment[J]. Journal of Clinical Hepatology, 2015, 31(7): 1176-1179. doi: 10.3969/j.issn.1001-5256.2015.07.045 |
[7] | Gao HuiXia, Liu YuZhen, Lu JianHua, Ye LiHong, Dai ErHei. Correlation of Foxp3 + Tregs and TGFβ1 expression with inflammation in livers of patients with primary biliary cirrhosis[J]. Journal of Clinical Hepatology, 2012, 28(12): 952-955. |
[9] | Kang HaiYan, Dong JiangLong, Wang JianBin, Li BingShun, Zhang HongXia. Relationship between transforming growth factor β1 and liver fibrosis and liver function in 260 patients with hepatitis B [J]. Journal of Clinical Hepatology, 2009, 25(1): 61-62. |
[10] | Zhan GuoQing, Zheng SanJu, Zhu Lin, Li JinKe, Hu Bo, Xie XingRong. Protective effect of tiopionin on liver injury caused by transcatheter arterial chemoembolization in liver carcinoma.[J]. Journal of Clinical Hepatology, 2009, 25(1): 48-50. |
[11] | Xu TingTing, Jiang MiaoNa, Jia YuJie, Che Ying. Ganfukang's effect on transforming growth factor β1 and laminin of experimental liver fibrosis rats[J]. Journal of Clinical Hepatology, 2005, 21(1): 30-31. |
[12] | Ling YunFeng, Feng ZhenBo, He RuKun, Lu: ZiLi. Expression of TGFβ1、TGFβRⅠ and TGFβRⅡ in hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2005, 21(1): 35-37. |
[13] | Bi Qing, Cheng Lei, Cui LiAn, Zhang JunFu. The effect of Kangxianruanjian on TGF β1 and it's the recepters in liver fibrosis in rats[J]. Journal of Clinical Hepatology, 2002, 18(3): 181-182. |
[15] | Zhu YingHua, Song HongLi, Zhang Yi, Yu Guang, Han JiJin. The Clinieal study about interleukin-1 and tumor necrosis factor Alpha in hepatocirrhosis[J]. Journal of Clinical Hepatology, 2001, 17(4): 233-234. |
[16] | Li QingHua, Li Hui, Qin ChengYong, Han GuoQing. The significance of urine transforming growth factor-β1 (TGF-β1) and serum procollagen type Ⅲ (PCⅢ) , collagen type Ⅳ (Ⅳ-C) , hyaluronic (HA) and laminin (LN) in patient with chronic HBV related liver disease[J]. Journal of Clinical Hepatology, 2001, 17(3): 161-162. |
[17] | Zhang Min, Zhang LingXia, Xin ShaoJie, Zhao JingMin, Wang SongShan, Wang LinJie. The relationship between transforming growth factor β1 and liver fibrosis[J]. Journal of Clinical Hepatology, 2000, 16(1): 32-33. |